24/7 Support Number +91-9137-44-1392

Dr Nirmal Raut

Dr. Nirmal Raut 

Dr. Nirmal Raut is a Medical Oncologist in Mumbai with 20+ years of experience in this field. He is currently associated with two hospitals namely Terna Speciality Hospital & Research Centre, Navi Mumbai, and Bhaktivedanta Hospital & Research Centre, Mira Road. He has a special skill in managing various solid and hematological malignancies in adult and pediatric patients.


Dr. Nirmal Raut has major interventions in the following medical specialties –

  • Radiation Oncology

He is an expert in providing various treatments from –


  • MD Radiotherapy – Tata Memorial Hospital, Mumbai
  • MBBS – King Edward Memorial Hospital and Seth Gordhandas Sunderdas Medical College (2000)
  • MD – Radiotherapy – Tata Memorial Hospital, Mumbai (2006)


Dr. Nirmal Raut is a well-known oncologist in Mumbai specializing in Radiation Oncology. He aims to address and alleviate the fear associated with cancer diagnosis among patients by providing emotional support and a compassionate approach to help them cope with the psychological challenges of cancer. His objective is to provide comprehensive care for cancer patients at affordable costs to make the treatments accessible for all. He has gained immense proficiency and skilled competency by working in various hospitals and centers from –

  • 2003-2009 Senior Registrar in Tata Memorial Hospital, 
  • 2009-2012 Consultant in Asian Institute of Medical Sciences
  • 2012-Present Senior Consultant in Bhaktivedanta Hospital & Research Centre
  • 2012-Present Jupiter Hospital in Consultant Medical Oncologist


  • European Society of Medical Oncology (ESMO)


Dr. Nirmal Raut has authored more than 40 national and international publications. Some of the few recent publications are –

Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001).

Comprehensive ctDNA analysis to identify genome-instability and actionable mutation landscape in gynecologic cancers.

Liquid and tissue profiling of somatic mutational landscape of non-small cell lung cancer from an Indian cohort.

Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.

Comprehensive plasma genotyping reveals mutational signatures that confer resistance to tyrosine kinase inhibitors (TKI) in patients with advanced lung cancer.

Effect of circulating tumor cells distribution in treatment naive and treated patients with advance stage breast cancer on disease burden.

Identification of novel actionable SNVs via targeted comprehensive genome profiling in patients with gallbladder and cholangiocarcinoma cancer.

Awards and Recognitions

  • Brainstem Glioma- Concurrent Temozolomide and Radiation (Red Journal)
  • Lung Cancer Epidemiology in India -Indian Journal of Cancer
  • NACT in Breast Cancer- where are we now? IJMPO


  • MBBS (KEM Hospital)
  • MD (Tata Memorial Hospital)
  • European Certification in Medical Oncology
  • Masters in Molecular Oncology (Spain)

Registration Details

  • Maharashtra Medical Council- Registration No. (2002042060)

© 2024 Uhapo Health Services (P) Ltd.

× How may I help you?